Amino Acids for Cardiac Surgery Associated AKI
- Registration Number
- NCT07001098
- Lead Sponsor
- Stanford University
- Brief Summary
The purpose of this study is to assess the feasibility of amino acid infusions in pediatric cardiac surgery patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Undergoing cardiac surgery and expected to be high risk
Exclusion Criteria
- preoperative extracorporeal organ support
- CKD history (GFR<60ml/min/1.73m2 [≤1year] and GFR<90ml/min/1.73m2 [>1 year])
- serum creatinine defined preoperative AKI.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Amino acid Amino Acids Participants receive amino acids for up to 3 days starting at the time of their cardiac surgery Placebo Placebo Participants receive equivalent volume of placebo for up to 3 days starting at the time of their cardiac surgery
- Primary Outcome Measures
Name Time Method Number of Participants with Amino acids Related Adverse Events Baseline, Daily during infusion upto 48 hours after completion of infusion (upto 5 days)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie amino acid infusion's potential to prevent acute kidney injury in pediatric cardiac surgery patients?
How does amino acid therapy compare to standard-of-care treatments for cardiac surgery-associated acute kidney injury in infants?
Which biomarkers are associated with acute kidney injury risk in pediatric cardiac surgery to guide amino acid therapy eligibility?
What adverse events are reported with amino acid infusions in neonatal and pediatric populations during cardiac recovery?
Are there combination therapies involving amino acids and renoprotective agents for acute kidney injury prevention in congenital heart disease?
Trial Locations
- Locations (1)
Lucile Packard Children's Hospital
🇺🇸Palo Alto, California, United States
Lucile Packard Children's Hospital🇺🇸Palo Alto, California, United States